Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Care Reform: The Excise Tax Was Only the Beginning

Executive Summary

The excise tax has been the medical device industry's main concern about pending health care reform, but other changes are taking place that will alter the market and potentially have a greater impact on sales and profits than the 2.3% tax. Specifically, device manufacturers' customers are at the beginning of changes that will alter reimbursement from the CMS to reflect adherence to standards of "best medical practices" tied to quality patient outcomes.

You may also be interested in...



Provider Trends: ACOs Begin to Take Shape

A new health-care delivery mode that could drastically alter how the industry is run took another significant step forward at the end of March, when the US Department of Health and Human Services issued proposed rules to govern Accountable Care Organizations. ACOs are designed to create strong networks of physicians and hospitals with aligned incentives focused on patient quality of care and costs. To gain some insight on possible future implications of ACOs for the medical device industry, Medtech Insight recently spoke with Ron Wince, president and CEO of the consulting firm Guidon Performance Solutions.

Health Care Reform: Further Taxing The Device Innovation Model

The tax on medical devices was a late addition to the health reform legislation but it quickly became the industry's focal point over concerns that, in an already difficult environment, this added burden could threaten to disrupt the traditional device innovation model.

AdvaMed Leaders Discuss Challenges Ahead for Device Industry

Changes in health care's regulatory landscape could have a negative effect on device innovation. In the following exclusive interview, James Mazzo, newly appointed chairman of the Advanced Medical Technology Association, along with AdvaMed president and CEO Stephen J. Ubl, discuss with Medtech Insight the hurdles facing the medical device industry today.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel